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 2 
ABSTRACT 27 
Cancer-causing HPV E6 oncoproteins have a Class I PDZ-binding motif (PBM) on 28 
their C-terminus, which plays critical roles that are related to HPV life cycle and HPV-29 
induced malignancies. E6 oncoproteins use these PBMs to interact with, and target 30 
for proteasome-mediated degradation, a plethora of cellular substrates that contain 31 
PDZ domains and which are involved in the regulation of various cellular pathways.  32 
In this study, we show that both HPV-16 and HPV-18 E6 can interact with Na+/H+ 33 
exchange regulatory factor 2 (NHERF-2), a PDZ domain-containing protein, which 34 
among other cellular functions also behaves as a tumor suppressor regulating 35 
endothelial proliferation. The interaction between the E6 oncoproteins and NHERF-2 36 
is PBM-dependent and results in proteasome-mediated degradation of NHERF-2.  37 
We further confirmed this effect in cells derived from HPV-16 and HPV-18 positive 38 
cervical tumors, where we show that NHERF-2 protein turnover is increased in the 39 
presence of E6.  Finally, our data indicate that E6-mediated NHERF-2 degradation 40 
results in p27 downregulation and cyclin D1 upregulation, leading to accelerated 41 
cellular proliferation.  To our knowledge, this is the first report to demonstrate that E6 42 
oncoproteins can stimulate cell proliferation by indirectly regulating p27 via targeting 43 
a PDZ domain-containing protein.  44 
 45 
IMPORTANCE 46 
This study links HPV-16 and HPV-18 E6 oncoproteins to the modulation of cellular 47 
proliferation. The PDZ domain-containing protein NHERF-2 is a tumor suppressor, 48 
shown to regulate endothelial proliferation, and here we demonstrate that NHERF-2 49 
is targeted by HPV E6 for proteasome-mediated degradation. Interestingly, this 50 
indirectly affects p27, cyclin D1 and CDK4 protein levels and consequently affects 51 
cell proliferation. Hence, this study provides information that will improve our 52 
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 3 
understanding of the molecular basis for HPV E6 function, and it also highlights the 53 
importance of the PDZ domain-containing protein NHERF2 and its tumor suppressive 54 
role in regulating cell proliferation. 55 
 56 
Keywords: HPV, E6 oncoprotein, cervical cancer, NHERF-2, p27, cyclin D1, cell 57 
proliferation 58 
 59 
INTRODUCTION  60 
Human papillomaviruses (HPVs) are small DNA tumor viruses shown to be the 61 
causative agents of cervical cancer, other anogenital cancers, and a number of head 62 
and neck cancers (1) (2) (3). Of these, cervical cancer is the most predominant 63 
disease caused by HPVs, with more than 600,000 cancers annually worldwide (4).  64 
Approximately fifteen mucosotropic HPV types, which are associated with human 65 
malignancies, are referred to as High-risk (HR) types (1).  HPV-16 and -18 are the 66 
most common HR HPV types and are responsible for approximately 80% of cervical 67 
cancers worldwide, while the remaining 20% are caused by the other HR types (5).  68 
Numerous studies have shown that the collaborative actions of the two major viral 69 
oncoproteins, E6 and E7, are responsible for the development and maintenance of 70 
HPV-mediated malignancies (6).  These two oncoproteins control various cellular 71 
pathways with the aim of maintaining an optimal cellular environment for viral 72 
replication. However, in instances where this is perturbed, it can lead to initial 73 
changes to the infected cells, which can eventually result in malignant transformation 74 
(7).  HPV E7 stimulates cell cycle progression by targeting the retinoblastoma tumor 75 
suppressor (pRB) and the other two pocket proteins, p107 and 130 (8) (9), while E6 76 
interferes with apoptosis by targeting the tumor suppressor p53 (p53) (10).  In 77 
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 4 
addition to p53 protein regulation, E6 also regulates p53 gene transactivation via 78 
abolishing p53 transcriptional transactivation activity (5) (6).  79 
Although E6 targeting of p53 is one of the crucial aspects in HPV-induced 80 
malignancies, there are also other important functions of E6 that contribute to 81 
malignant progression. One of these is the ability of HR HPV E6 oncoproteins to 82 
interact with the so-called PDZ domain-containing proteins.  The E6 proteins from all 83 
of the HR HPV types contain 4 amino acids on their extreme C-termini that 84 
correspond to a Class I (PSD-95/Dlg-1/ZO-1) binding motif (PBM).  Conversely, this 85 
motif is absent from the E6 proteins of Low-risk (LR) HPV types, which cause benign 86 
warts (11).  Multiple studies have shown that the PBM plays critical roles in various 87 
E6 functions that are related to HPV life cycle and malignant transformation.  PBM-88 
PDZ interactions lead to increased proliferation of infected cells and are required for 89 
optimal amplification and maintenance of viral episomes (12) (13) (14) (15) (16).  90 
These interactions also play important roles in the process of HPV-induced cellular 91 
transformation in tissue culture and in transgenic mouse models, where they were 92 
shown to be required for E6’s ability to induce epithelial tumors in cooperation with 93 
E7 (17) (18) (19) (12) (20).   94 
HPV E6 oncoproteins interact with a number of PDZ domain-containing proteins that 95 
belong to the membrane-associated guanylate kinase (MAGUK) family; and the most 96 
extensively studied interacting partners of E6 include the human homologues of the 97 
Drosophila disc large protein (hDlg), Scribble (hScrib) and the membrane-associated 98 
guanylate kinase with inverted orientation (MAGI) family protein members (11). 99 
MAGUK proteins have multiple PDZ domains and, by forming simultaneous 100 
interactions with a number of membrane and cytoplasm-associated cellular proteins, 101 
they can serve as scaffolds in forming large complexes.  Many of them behave as 102 
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 5 
tumor suppressors and are also involved in the regulation of cell polarity and cell-cell 103 
contacts (21) (22).  In addition to the MAGUK family member proteins, some other 104 
PDZ domain-containing proteins involved in cellular signaling and trafficking have 105 
also been characterized as E6 substrates (22) (23). One example is a member of the 106 
Na+/H+ Exchange Regulatory Factor (NHERF) protein family, NHERF-1, which is 107 
involved in a number of important cellular processes such as signaling and 108 
transformation (24). HPV-16 E6 can target NHERF-1 for degradation at the 109 
proteasome, leading to the activation of the PI3K/AKT signaling pathway, which is an 110 
important factor in carcinogenesis (25).   111 
Another member of the NHERF protein family is NHERF-2, which is involved in the 112 
regulation of lamellopodia formation and cell migration, and which interacts with the 113 
N-cadherin/β catenin (N-Cad/Cat) complex and the PDGFR in epithelial cells (26).  114 
NHERF-2 also acts as a scaffold protein for plasma membrane proteins and 115 
members of the ezrin/moesin/radixin family, thereby providing a connection between 116 
these proteins and the actin cytoskeleton, and controls their surface expression (27).  117 
In addition, more recent studies indicate that NHERF-2 is a negative regulator of 118 
endothelial proliferation, which is mediated via the cyclin-dependent kinase inhibitor 119 
p27 (28).   120 
The fact that NHERF-2 is a PDZ domain-containing protein and is structurally related 121 
to NHERF-1, which was previously characterized as a HR HPV-16 E6 oncoprotein 122 
substrate, and that it is involved in the regulation of cellular proliferation, suggested 123 
that NHERF-2 might also be a cellular substrate of the HPV-16 E6 oncoprotein. Here, 124 
we report not only that NHERF-2 is a cellular target of the HPV-16 E6 oncoprotein, 125 
but also that it binds to other HPV E6 proteins via their PBM motifs. We further report 126 
that both HPV-16 and HPV-18 E6 target NHERF-2 for proteasome-mediated 127 
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 6 
degradation. NHERF-2 ablation in the presence of HPV E6 leads to p27 128 
downregulation and, consequently, this results in increased cellular proliferation.   129 
RESULTS 130 
E6 oncoproteins from HPV-16, HPV-18 and HPV-33 interact with NHERF-2. 131 
It is well known that the E6 oncoproteins of cancer-causing types of HPV have PBMs 132 
through which they can interact with a panel of PDZ domain-containing proteins to 133 
elicit a cellular response (11) (21) (22). One of these PDZ-domain containing proteins 134 
is NHERF-1, structurally related to NHERF-2, for which it was previously reported to 135 
be bound by HPV-16 E6 and consequently degraded at the proteasome (25). We 136 
therefore, firstly, wanted to investigate whether the PDZ domain-containing NHERF-2 137 
protein could complex with HPV E6 oncoproteins in vitro. A series of GST pulldown 138 
assays were performed, where in vitro translated NHERF-2 was incubated with GST-139 
16 E6, GST-18 E6, GST-33 E6, GST-18 E6∆PBM, or GST alone for control.  The 140 
results in Figure 1A show that HPV-16 E6, HPV-18 E6 and HPV-33 E6 all bind to 141 
NHERF-2 and the HPV-16 E6 interaction with NHERF-2 appears to be the strongest, 142 
while there is no association between HPV-18 E6∆PBM and NHERF-2. To confirm 143 
that the interaction was PDZ-PBM-mediated in each of the HPV types, the assay was 144 
repeated, including GST fusion proteins with HPV 16 and HPV-33 E6 proteins 145 
deleted for the PBM (HPV-16 E6∆PBM and HPV-33 E6∆PBM). The results in Figure 146 
1B show that there is no association between NHERF-2 and HPV E6 in the absence 147 
of a functional PDZ-binding domain.  These results suggest that NHERF-2 can 148 
complex with multiple HR E6 proteins and that the interactions are PDZ dependent. 149 
We then proceeded to confirm that the interactions between E6s and NHERF-2 also 150 
occur in cultured cells.  HEK-293 cells were transfected with HA-tagged NHERF-2; 151 
after overnight incubation the cells were harvested and proteins extracted in E1A 152 
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 7 
buffer. The extracts were incubated with GST-16 E6, GST-18 E6, GST-11 E6, GST-153 
33 E6, or GST alone for control. Bound proteins were detected by SDS-PAGE and 154 
Western blot and the results are shown in Figure 1B. In this setting, we observed that 155 
NHERF-2 binds with equal strength to HPV-16 E6 and HPV-18 E6, while HPV-33 E6 156 
bound NHERF-2 somewhat weakly. No interaction was detected between the LR 157 
HPV-11 E6 and NHERF-2, which was expected, since HPV-11 E6 lacks a PBM. 158 
Further, to test whether endogenous NHERF2 interacts with E6 proteins, we 159 
performed GST pulldown assays as already described, using lysates from C33-A 160 
cells. The results in Figure 1C show that all the HR E6 oncoproteins tested bind to 161 
NHERF-2, with HPV-16 E6 being the strongest interactor, while no interaction with 162 
HPV-11 E6 was detected. Together, these results suggest that, although multiple HR 163 
E6 oncoproteins bind to NHERF-2, the principal interacting partner is likely to be 164 
HPV-16 E6.      165 
 166 
HPV-16 E6, HPV-18 E6 and HPV-33 E6 induce NHERF-2 degradation via the 167 
proteasome in a PBM-dependent manner 168 
After we had demonstrated that HPV-16 E6, HPV-18 E6 and HPV-33 E6 169 
oncoproteins can interact with NHERF-2, the next obvious question was to 170 
investigate the possible consequences of the E6-NHERF-2 interactions.  Since 171 
substrate degradation is a characteristic of the HPV E6-PDZ interaction (11) (29), we 172 
examined whether HPV E6 oncoproteins can likewise direct the degradation of 173 
NHERF-2.  To do this, 16 E6, 18 E6, 33 E6 and 11 E6 were translated in vitro, and 174 
co-incubated with in vitro-translated NHERF-2 for 1 or 2 h at 30°C. The level of 175 
NHERF-2 protein remaining was ascertained by SDS–PAGE and autoradiography.  176 
The results in Figure 2A show that HPV-16 E6 and HPV-18 E6 were efficient in 177 
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 8 
inducing the degradation of NHERF-2, while HPV-33 E6 induced NHERF-2 178 
degradation less efficiently and HPV-11 E6 did not induce any NHERF-2 179 
degradation.  The weaker (HPV-33 E6) or absent (HPV-11 E6) degradative activity is 180 
consistent with their lower binding affinity or complete lack of interaction with NHERF-181 
2 respectively. 182 
   183 
To investigate whether E6 oncoproteins can degrade NHERF-2 in cultured cells, 184 
HEK-293 cells were co-transfected with a plasmid expressing HA-tagged NHERF-2 185 
either alone or in combination with HPV-16 E6, HPV-18 E6, HPV-11 E6 or HPV-33 186 
E6 expression plasmids, in two sets of experiments. In one set of experiments, the 187 
transfected cells were left untreated, while in the other, the transfected cells were 188 
treated with the proteasomal inhibitor Bortezomib (BTZ).  After 24 h the cells were 189 
harvested and NHERF-2 levels analyzed by immunoblotting. The Western blot 190 
results, together with quantitative analysis based on band densitometry in Figure 2B 191 
show that NHERF-2 protein levels are significantly reduced by more than 4 fold in 192 
cells expressing HPV-16 E6, and by more than 2 fold in those expressing HPV-18 E6 193 
and HPV-33 E6.  This result indicates that HPV-16 E6 is the most efficient at inducing 194 
NHERF-2 degradation, followed by HPV-18 E6 and HPV-33 E6. In cells expressing 195 
the LR HPV-11 E6, there was no significant effect on NHERF-2 levels. Interestingly, 196 
when the same transfected cells were treated with BTZ, E6-induced degradation of 197 
NHERF-2 was prevented, indicating that it was proteasome-mediated.   198 
To further examine the observed E6 effect on NHERF-2, we compared the 199 
expression levels of NHERF-2 in HPV-negative C33-A cells, HPV-18-positive HeLa 200 
cells, and HPV-16-positive CaSki and SiHa cells by performing Western blot analysis.   201 
It is clearly visible in Figure 2C that endogenous NHERF-2 is abundant in C33-A 202 
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 9 
cells, while lower level was detected in HeLa cells and it was almost absent in CaSki 203 
and SiHa cells. This suggests that the protein turnover rates of endogenous NHERF-204 
2 are increased in the presence of HPV-18 E6, and even further increased in the 205 
presence of HPV-16 E6. Furthermore, it implies that the protein turnover of NHERF-2 206 
is more efficiently regulated by HPV-16 E6, which could be attributed to the stronger 207 
binding capacity of HPV-16 E6 for NHERF-2 as seen in Figure 1C. To additionally 208 
corroborate our initial observations shown in Figures 2A and B, where we showed 209 
that NHERF-2 is targeted for proteasome-mediated degradation by HPV-16 E6 and 210 
HPV-18 E6, we cultured the same HPV-positive and HPV-negative cell lines used in 211 
Figure 2C, in the presence or absence of the proteasomal inhibitor BTZ. After 212 
treatment, cells were harvested and the levels of NHERF-2 protein were analyzed by 213 
Western blotting. In the presence of BTZ, a sharp increase in the levels of NHERF-2 214 
protein was observed in both HPV-16 and HPV-18-positive cell lines compared with 215 
the HPV-negative cell lines, where no such increase was observed (Figure 2D); 216 
suggesting that in HPV-positive cell lines derived from cervical tumors, NHERF-2 is a 217 
subject to proteasome-mediated degradation by E6. 218 
Since cancer-causing HPV E6 proteins have PBMs through which they can interact 219 
with a specific panel of proteins (11); including NHERF-2, and then target them for 220 
proteasome-mediated degradation, we wondered whether PBM-PDZ interactions are 221 
required for NHERF-2 degradation. HEK-293 cells were co-transfected with a 222 
plasmid expressing HA-tagged NHERF-2 and plasmids expressing either HPV-16 E6 223 
or HPV-18 E6, or with plasmids expressing respective mutant E6 proteins which lack 224 
PDZ binding motifs (16 E6ΔPBM or 18 E6ΔPBM) (30).  Again, according to Western 225 
blot with quantitative analysis based on band densitometry, (Figure 3) shows that 226 
NHERF-2 protein levels were significantly downregulated in HEK-293 cells 227 
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expressing wild type HPV-16 E6 and HPV-18 E6, but not in those expressing the 228 
mutant HPV-16 E6ΔPBM or HPV-18 E6ΔPBM, suggesting that the E6 PBM is 229 
required for E6-proteasome-mediated degradation of NHERF-2. 230 
 231 
HPV E6 silencing restores nuclear pool of NHERF-2  232 
Having found that HPV E6 oncoproteins could degrade NHERF-2, we were next 233 
interested in assessing which cellular populations of NHERF-2 were being targeted, 234 
as previous studies have indicated both nuclear and cytoplasmic localization of 235 
NHERF-2 within the cell (28).   In addition, NHERF-1, structurally related protein to 236 
NHERF-2, was previously reported to be detected in the cytoplasm, but absent from 237 
the nucleus in HPV-16 E6/E7-positive primary human foreskin keratinocytes (HFKs) 238 
(25). To examine this, we performed siRNA ablation of E6/E7, and also ablated E6AP 239 
expression, as an alternative means of reducing E6 expression levels (31) in HeLa 240 
and CaSki cells. After 72 h, the proteins from one set of cells were extracted with 241 
E1A buffer and NHERF-2 protein levels were analyzed by Western blotting; the levels 242 
of p53 protein were also analyzed as a control of E6/E7 silencing. The results in 243 
Figure 4A. show NHERF-2 upregulation in both HeLa and CaSki cells, upon 244 
treatment with siRNA against E6/E7 or E6AP.  Simultaneously, cells were fixed and 245 
immunolabeled, and the pattern of NHERF-2 localization was monitored by confocal 246 
microscopy.  Interestingly, E6/E7 downregulation induced the major recovery of 247 
NHERF-2 in the nucleus.  This pattern was consistent in all HPV-positive cell lines 248 
used in the experiment (HeLa, CaSki and Siha) (Figures 4B, C and D). To further 249 
confirm this, we overexpressed HPV-16 E6 in HFKs.  After 24 h, cells were fixed and 250 
immunolabeled, and the cellular localization of NHERF-2 was monitored by confocal 251 
microscopy.  As indicated in Figure 4 E, cells that ectopically express 16 E6 exhibited 252 
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reduced levels of nuclear NHERF-2.  Taken together, these results suggest that E6 253 
preferentially targets the nuclear pool of NHERF-2, similarly to NHERF-1 (25).   254 
 255 
E6 degradation of NHERF-2 regulates the expression of key cell cycle-related 256 
proteins 257 
Cell cycle-related proteins including cyclins, such as cyclin D; cyclin-dependent 258 
kinases, such as CDK2 and CDK4; and cyclin-dependent kinase inhibitors, such as 259 
p21 and p27, enable cells to divide (32). For example, p27 is a critical cell cycle 260 
regulator, serving as an inhibitor of both CDK2 and CDK4, and its accumulation has 261 
been noted to result in cell cycle arrest at the G1/S phase (33) (34).  In addition, more 262 
recent reports indicate that NHERF-2 has an upregulatory effect on p27 and thus 263 
acts as a negative regulator of endothelial cell proliferation (28). Therefore, we asked 264 
whether the E6-induced proteasome-mediated degradation of NHERF-2 could have 265 
an influence on some of these cell cycle-related proteins, and especially on p27. 266 
Hence, we co-transfected HEK-293 cells with plasmids expressing HA-NHERF-2 and 267 
those expressing either HPV-16 or HPV-18 E6 wild type, or their respective mutated 268 
forms HPV-16 E6ΔPBM or HPV-18 E6ΔPBM.  Expectedly, as shown in Figure 5A, 269 
the protein levels of both p27 and NHERF-2 increase when cells exogenously 270 
express NHERF-2 alone, but not when NHERF-2 is co-expressed with either HPV-16 271 
E6 or HPV-18 E6 wild-types. Co-expression of either of the ΔPBM mutants had no 272 
effect on p27 or NHERF-2 levels (relative densitometries in the bottom panel of 273 
Figure 5A).  274 
On the contrary, exogenous expression of NHERF-2 led to a decrease in cyclin D1 275 
and CDK4 which was reversed upon co-expression of the wild-type E6, but not the 276 
ΔPBM mutants (relative densitometries in the bottom panel of Figure 5B). These data 277 
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suggest that the E6-induced degradation of NHERF-2 results in p27 downregulation 278 
and upregulation of cyclin D1 and CDK4, which may in turn influence cell 279 
proliferation.  280 
Since NHERF-2 overexpression enhances p27 protein levels, while E6 degradation 281 
of NHERF-2 downregulates it, we wanted to investigate whether the effects of E6 on 282 
p27 are exclusively NHERF-2-dependent or if other cellular mechanisms are involved 283 
in this process. To do this, HEK-293 cells were co-transfected with plasmids 284 
expressing HA-tagged NHERF-2 and HPV-16 E6ΔPBM in the presence or absence 285 
of siRNA against NHERF-2 (siNHERF-2).  After 72 h NHERF-2 and p27 levels were 286 
analyzed by Western blotting. As shown in Figure 5C, p27 levels were significantly 287 
increased (relative densitometries in the bottom panel of Figure 5C) in cells 288 
ectopically expressing NHERF-2, and remained high in cells co-expressing NHERF-2 289 
and HPV-16 E6ΔPBM, presumably because the E6ΔPBM cannot induce NHERF-2 290 
degradation, as shown in Figure 5A.  Interestingly, when NHERF-2 was co-291 
expressed with 16 E6ΔPBM in the presence of siNHERF-2, no significant 292 
upregulation of p27 was observed; suggesting that the downregulatory effects of E6 293 
on p27 levels occur exclusively via NHERF-2.   294 
To further confirm the underlying mechanisms, Hela cells were transfected with 295 
siRNA against E6/E7 and E6AP, since loss of E6AP can destabilize E6 (31); siRNA 296 
against luciferase was used as a control.  After 72 h, proteins from cellular lysates 297 
were analyzed by Western blotting for NHERF-2, p27 and α-actinin.  The results in 298 
Figure 5D show that ablation of E6 either by using siRNAE6/E7 or siE6AP leads to 299 
upregulation of NHERF-2 and p27.  Secondly, we transfected CaSki cells with siRNA 300 
directed against E6AP and NHERF-2, in combination or separately, using siRNA 301 
against luciferase as a control. In this setting, we also analyzed the effect on p27 302 
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levels of a double knockdown of both E6AP and NHERF-2. After 72 h, cellular lysates 303 
were analyzed by Western blotting for NHERF-2, p27, and α-actinin. The results in 304 
Figure 5E confirm that downregulation of E6 (through siE6AP) leads to upregulation 305 
of NHERF-2 and p27, and interestingly, in the cells that were doubly knocked down 306 
for E6AP and NHERF-2, there was little or no upregulation of p27.  We further 307 
explored the endogenous p27 protein levels in relation to those of NHERF-2 and p53 308 
in HPV-negative C33-A cells, HPV-18-positive HeLa cells, and HPV-16-positive 309 
CaSki and SiHa cells by performing Western blot analysis. As shown in Figure 5F, 310 
endogenous NHERF-2 protein levels are again abundant in C33-A cells compared 311 
with HeLa, CaSki and SiHa cells. Interestingly, a similar trend is also observed for the 312 
endogenous protein levels of both p27 and p53, where p27 and p53 protein levels 313 
are abundant in C33-A cells compared with HeLa, CaSki and SiHa cells.  Taken 314 
together, these results additionally support the notion that the effects of E6 on p27 315 
expression levels are primarily dependent on the E6/NHERF-2 interaction.     316 
 317 
HPV E6 increases cellular proliferative capacity by degrading NHERF-2 318 
Having shown that NHERF-2 overexpression can decrease Cyclin D1 and CDK4 319 
protein levels, while increasing p27 protein levels, we questioned whether this effect 320 
might affect cell proliferation; and if so, what influence E6-induced degradation of 321 
NHERF-2 might also have? NHERF-2 has been reported to negatively regulate 322 
endothelial cell proliferation (28), and studies suggest that p27 accumulation can 323 
inhibit the cyclin D1-CDK4 complex, leading to cell cycle arrest at G1/S (32), all of 324 
which makes these questions compelling. To answer them, hence, we transfected 325 
HEK-293 cells with empty vector (EV) or with vectors expressing HA-NHERF-2, HPV-326 
16 E6, HPV-18 E6, HPV-16 E6ΔPBM and HPV-18 E6ΔPBM alone or in combination 327 
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as indicated (Figure 6). Cell proliferation was then evaluated by the Uptiblue cell 328 
proliferation assay and the results are shown in Figure 6. Exogenous expression of 329 
NHERF-2 alone significantly decreases proliferation, compared with EV-transfected 330 
cells. However, proliferation significantly increased in cells co-expressing NHERF-2 331 
with HPV-16 or HPV-18 E6 wild-type, but not with the E6 ΔPBM mutants (Figure 6A 332 
and B), indicating that the E6ΔPBM mutants were not able to target NHERF-2 like the 333 
wild type E6s, but were still able to stimulate cell proliferation via other mechanisms 334 
(35). When cells were transfected with plasmids expressing HPV-16 E6 alone, a 335 
significant increase in cell proliferation is observed compared with EV-transfected 336 
cells, while transfection with the HPV-16 E6ΔPBM mutant alone shows no significant 337 
change in cell proliferation (Figure 6A). Furthermore, in cells ectopically expressing 338 
HPV-16 E6 or HPV-16 E6ΔPBM alone, cellular proliferation was stimulated more 339 
strongly than in cells co-expressing NHERF-2 (Figure 6A), suggesting that the 340 
difference in cell proliferation maybe be due to the anti-proliferative effects of 341 
NHERF-2. To confirm this, expression of NHERF-2 was modulated in HPV-negative 342 
C33-A cells and HFK cells, HFK cells containing the HPV16 E6 genome 343 
(HFK_HPV16 E6), HPV-18-positive HeLa cells, and HPV-16-positive CaSki and SiHa 344 
cells. Each  cell line was each transfected with a control siRNA (siLuc) or NHERF-2 345 
siRNA (siNHERF-2) as indicated. After 48 h, a scratch wound was generated in the 346 
confluent cells and immediately photographed. Cells were again photographed again 347 
24 h later and gap closure, which represents wound healing, was calculated. Figure 348 
6C shows a representative assay, together with Western blot analysis and a 349 
histogram of the collated results of at least three assays. Compared with control 350 
siRNA (siLuc) groups, ablation of NHERF-2 using siRNA caused not only a decrease 351 
in the endogenous protein levels of NHERF-2, but also significantly increased wound 352 
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healing in both HPV-negative and HPV-positive cell lines thereby confirming the anti-353 
proliferative effects of NHERF-2 in these different cell lines. Taken together, these 354 
data suggest that NHERF-2 downregulation can increase cell proliferation, while its 355 
overexpression can decrease cell proliferation through upregulation of p27 and 356 
inhibition of cyclin D1 and CDK4. Moreover, HPV E6-mediated NHERF-2 degradation 357 
can lead to an increase in cellular proliferation. This is of obvious importance in 358 
inducing a cellular state permissive for viral DNA replication, but can also contribute 359 
to the ability of HR HPV types to cause malignancy. 360 
 361 
DISCUSSION 362 
Numerous studies have demonstrated that HR HPV E6 oncoproteins bind and 363 
degrade various PDZ-domain containing proteins (11) and, so far, the majority of the 364 
identified PDZ targets of E6 belong to the MAGUK protein family. Two of these 365 
MAGUK family members, hScrib and MAGI-I, are preferentially targeted by HPV-16 366 
E6 (36) and HPV-18 E6 (37), respectively. Interestingly, it has been shown that hDIg, 367 
a third member of the MAGUK protein family, can be bound by E6 oncoproteins from 368 
a wide range of HR HPV types, indicating the evolutionary conservation and 369 
importance of proteins involved in various E6 functions (38).  Furthermore, it was 370 
reported that HPV-16 E6 can also bind and degrade NHERF-1, a PDZ domain-371 
containing protein and a member of the NHERF protein family. HPV-16 E6 372 
degradation of NHERF-1 results in the activation of the PI3K/AKT signaling pathway, 373 
which plays a crucial role in carcinogenesis (25). Most LR HPV E6 oncoproteins do 374 
not have a PBM, while all of the HR types contain a Class I PBM, implying that this 375 
HR hallmark plays a key feature in HPV-mediated carcinogenesis. This is further 376 
supported by tissue culture and in vivo animal model studies, which showed that the 377 
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interactions between HPV E6 and PDZ-domain substrates play a major role in 378 
cellular transformation, in cooperation with E7, and in the induction of epithelial 379 
tumors (17) (18) (19) (12) (20). So far, however, little is known about the effect of 380 
HPV E6 oncoproteins on the PDZ-domain containing protein NHERF-2, even though 381 
NHERF-2 is structurally related to NHERF-1, which was previously characterized as 382 
a HR HPV-16 E6 oncoprotein substrate (25). We therefore, speculated that NHERF-383 
2, which, like NHERF-1, is involved in various cellular processes such as signaling 384 
and proliferation control, is also likely to be a cellular substrate of some of the HPV 385 
E6 oncoproteins.    386 
 387 
In this study, we report that the E6 oncoproteins of HPV-16, HPV-18 and HPV-33 can 388 
interact with NHERF-2. Our data indicate that the E6-NHERF-2 interaction is PDZ-389 
PBM mediated and that the binding with HPV-16 E6 is the strongest, less strong with 390 
HPV-18 E6 and rather weak with HPV-33 E6, while LR 11 E6 on the other hand does 391 
not bind NHERF-2. The interactions of HPV-16, HPV-18 and HPV-33 E6 with 392 
NHERF-2 lead to its proteasome-mediated degradation both in vitro and in vivo.  Of 393 
the E6 oncoproteins examined, HPV-16 E6 is the most efficient inducer of NHERF-2 394 
degradation, while HPV-33 E6 is the least efficient, directly correlating with the 395 
intensity of their NHERF-2 binding. Previous studies have shown that NHERF-1, 396 
interacts exclusively with HPV-16 E6 (25). Interestingly, despite their structural 397 
similarities, this is not the case with NHERF-2, which can interact with multiple E6 398 
proteins. Although these two NHERF family proteins are similar, it is likely that 399 
variations within their PDZ domains influences selection of their interacting partners 400 
(39) (40).  Namely, it is well known that even a single amino acid change in the PBM 401 
of HPV E6 protein can alter the preferred target selection.  In addition, it has been 402 
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shown that other amino acids upstream of the canonical PDZ recognition motif in E6 403 
can influence the PBM-PDZ interactions and even minor changes in these amino 404 
acids can also have an effect on the strength of interaction (36) (40).  All of these can 405 
explain the differences in the strength of interactions between the different E6 406 
proteins and NHERF-2, as well as the corresponding differences in their degradative 407 
capabilities.   408 
 409 
In agreement with the overexpression assays, NHERF-2 turnover is also regulated by 410 
E6 and the proteasome in HPV-positive cells. Although the endogenous protein 411 
levels of NHERF-2 are significantly lower in HPV-16-positive CaSki and SiHa cells 412 
than in HPV-18 positive HeLa cells, it appears that the NHERF-2 protein turnover is 413 
regulated via the proteasome in all the HPV-positive cell lines tested, since NHERF-2 414 
levels are stabilized in the presence of proteasome inhibitors. Remarkably, however, 415 
even though the interaction between HPV-18 E6 and NHERF-2 is weaker compared 416 
to HPV-16 E6, it appears to be sufficient to induce proteasome-mediated NHERF-2 417 
degradation. This finding is further supported by the restoration of nuclear pool of 418 
NHERF-2, following ablation of E6 in HeLa, CaSki and SiHa cells. Conversely, this is 419 
not the case in the HPV-negative C33-A cell line, where in the presence of 420 
proteasome inhibitors, there is no significant increase in the expression levels of 421 
endogenous NHERF-2; indicating the importance of NHERF-2 regulation in the HPV-422 
life cycle and HPV-mediated malignancies.  423 
 424 
Previous studies revealed that E6 can induce cellular proliferation by deregulating the 425 
G1/S transition, which is thought to be mainly an E7-controlled function (41).  Our 426 
results provide new insights into the mechanisms used by HPV-16 E6 and HPV-18 427 
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E6 in involving p27 to induce cellular proliferation in epithelial cells.  Intriguingly, 428 
NHERF-2 can behave as a tumor suppressor since it negatively regulates endothelial 429 
proliferation primarily by upregulating the protein expression of p27 (28). We present 430 
new evidence for a direct role of E6 in manipulating NHERF-2 regulation of the cell 431 
proliferation mechanism in epithelial cells, where by targeting NHERF-2, E6 432 
downregulates p27 and increases the protein expression of cyclin D1 and CDK4, 433 
which ultimately results in increased cell proliferation. This is the first report showing 434 
an indirect effect of E6 on p27, which as a consequence, enhances cell proliferation. 435 
Previous studies have shown the importance of HPV E7 and p27 interactions for 436 
HPV-driven malignancies, indicating that HPV-16 and HPV-18 E7 proteins enhance 437 
cytoplasmic retention of p27, which results in an increased cellular proliferation; and 438 
this p27 localization to the cytoplasm was also revealed as a marker of poor 439 
prognosis for several cancer types (42)(43). Hence, it appears that HR HPV types 16 440 
and 18 have developed two autonomous mechanisms of targeting the p27 cellular 441 
pathway.  In one of them, E7 inactivates p27 by preserving it in the cytoplasm, 442 
resulting in increased cellular proliferation (42)(43), while in the other, HPV E6 targets 443 
the PDZ-domain containing protein NHERF-2 for proteasomal degradation, leading to 444 
the downregulation of p27 thereby promoting cellular proliferation. Both of these 445 
mechanisms emphasize the relevance of the p27 pathway for both HPV-life cycle 446 
and HPV-induced malignancies.    447 
 448 
MATERIALS AND METHODS 449 
Cell culture and transfections.  450 
Human foreskin keratinocytes (HFKs) and HFKs containing the HPV16 genome 451 
(HFK_HPV16 E6) were cultured in Keratinocyte serum-free media (K-SFM; Gibco) 452 
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and penicillin/streptomycin.  All other cells were cultured in Dulbecco's modified 453 
Eagle's medium (DMEM) with 10% fetal bovine serum (FBS) and 454 
penicillin/streptomycin (GIBCO). Cells were cultured at 37°C in an atmosphere 455 
enriched with 10% CO2.  HFKs, HFK_HPV16 E6, HEK-293 (human embryonic 456 
kidney), C33-A (Cervical carcinoma – HPV negative), HeLa (HPV-18 positive, 457 
cervical carcinoma), CaSKi (HPV-16 positive, cervical carcinoma) and SiHa (HPV-16 458 
positive, cervical carcinoma) were transfected using calcium phosphate precipitation 459 
(44) or Lipofectamine RNAimax (Invitrogen), Lipofectamine 2000 (Invitrogen) 460 
according to the manufacturer’s instructions.    461 
Plasmids. 462 
Wild-type hemagglutinin (HA)-tagged HPV-16 E6, HA-tagged 18 E6, HA-tagged 33 463 
E6, HA-tagged 11 E6, HA-tagged 16 E6ΔPBM, HA-tagged 18 E6ΔPBM and HA-464 
tagged NHERF-2, which have all been described previously (30) (45) (46) (29), were 465 
used.  Glutathione S-transferase (GST) fusion proteins GST-16 E6, GST-18 E6, 466 
GST-33 E6, GST-11 E6 and GST-18 E6∆PBM have also been previously described 467 
(31) (47) (48).     468 
 469 
Antibodies. 470 
The following antibodies were used: anti-NHERF-2, anti-p53 (DO-1), anti-D-actinin, 471 
anti-p21, anti-cyclin D1 and anti-CDK4, which were all purchased from Santa Cruz 472 
Biotechnology; Anti-HA-peroxidase (clone HA-7) (Sigma); E-galactosidase (LacZ) 473 
(Promega); Mouse and rabbit secondary antibodies conjugated to horseradish 474 
peroxidase (HRP) (DAKO); Rhodamine or Alexa Fluor (Invitrogen).     475 
 476 
Inhibitors.   477 
 478 
The following inhibitors were dissolved in DMSO and used at the indicated 479 
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concentrations: proteasome inhibitor Z-leu-leu-leu-al (CBZ (MG-132); Sigma) (50 µM) 480 
and proteasome inhibitor bortezomib (BTZ; Sigma) (10 µM).  Protease inhibitors 481 
Cocktail Set I (Calbiochem) was dissolved in water.   482 
 483 
Fusion protein purification and in vitro binding assays 484 
Glutathione S-transferase (GST) fusion protein synthesis in DH5D 485 
competent Escherichia coli cells and protein purification were performed as 486 
previously described (49).  Proteins were translated in vitro using a Promega TNT kit 487 
and radiolabeled with [35S] cysteine or [35S] methionine (Perkin Elmer). Equal 488 
amounts of in vitro translated proteins were added to GST fusion proteins bound to 489 
glutathione agarose (Sigma) and incubated for 1 h at 4°C. After extensive washing 490 
with phosphate-buffered saline (PBS) containing 0.25% NP-40, the bound proteins 491 
were analyzed by SDS-PAGE and autoradiography. 492 
GST pulldowns using cellular extracts were performed by incubating GST fusion 493 
proteins immobilized on glutathione agarose with cells extracted in E1A buffer (25 494 
mM HEPES, pH 7.0, 0.1% NP-40, 150 mM NaCl, plus protease inhibitor cocktail set I 495 
[Calbiochem]) for 1 h at 4°C on a rotating wheel. After extensive washing, the bound 496 
proteins were detected using SDS-PAGE and Western blotting. 497 
 498 
Immunofluorescence  499 
Cells were stained and fixed for immunofluorescence as previously described (48).  500 
In brief, HeLa, CaSki and SiHa cells were each grown overnight on glass coverslips 501 
before transfection with siRNA against luciferase, E6AP or E6/E7 as indicated for 72 502 
h and then fixed with 4% paraformaldehyde for 10 min at room temperature followed 503 
by permeabilization in PBS containing 0.1% Triton X-100. Immunostaining was 504 
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performed by incubating the coverslips in PBS containing antibodies against p53 505 
(Santa Cruz Biotechology) or NHERF-2 (Santa Cruz Biotechnology) as indicated 506 
overnight in a humidified chamber at 4°C.  Secondary anti-rabbit or anti-mouse 507 
conjugated with alexa fluor or rhodamine was used as appropriate (Invitrogen). 508 
Nuclei were labeled with DAPI. Coverslips were slide mounted using Fluoroshield 509 
Mounting Medium with DAPI (GR271388-1, Cambridge, UK). Confocal fluorescence 510 
microscopy was performed using laser scanning microscope Leica TCS SP8 X, 511 
equipped with a HC PL APO CS2 63×/1.40 oil objective, 405 nm diode laser, an 512 
argon and a supercontinuum excitation lasers (Leica Microsystems). Images were 513 
acquired by sequential scanning with the excitation at 405 nm for DAPI, 488 nm for 514 
Alexa488 and 570 nm for Rhodamine Red. Detection ranges were 413-460 nm for 515 
DAPI, 496-559 nm for Alexa488 and 578-650 nm for Rhodamine Red. 516 
 517 
In vitro degradation assays.   518 
Proteins were transcribed and translated in vitro in rabbit reticulocyte lysate using the 519 
Promega TNT system according to the manufacturer’s instructions.  The HPV-16 E6, 520 
-18 E6, -33 E6, -11 E6 proteins were radiolabeled with [35S]-cysteine while NHERF-2 521 
was labeled with [35S]-methionine. Degradation assays were performed as previously 522 
described (50).  Briefly, radiolabeled proteins were mixed and incubated for the 523 
indicated times at 30ºC.  Volumes were adjusted using water-primed lysate.  The 524 
remaining NHERF-2 was analyzed by SDS-PAGE and autoradiography.   525 
   526 
In vivo degradation assays. 527 
Transfected or non-transfected cells seeded (3.5 x 105) on 60 mm dishes were 528 
treated with either dimethyl sulfoxide (DMSO) alone as a control or with the 529 
 on O
ctober 15, 2019 at ICG
EB
http://jvi.asm
.org/
Downloaded from
 
 22 
proteasome inhibitors MG-132 or BTZ; both of which were dissolved in DMSO. Cells 530 
were harvested 24 h after treatment and cellular proteins extracted for analysis by 531 
Western blot. 532 
 533 
Cell proliferation assay. 534 
Cells were seeded into a 60 mm dish (3.5 x 105) in a total volume of 2.5 ml of cell 535 
culture medium. Cells were cultured overnight and were then transfected with either 536 
the Lipofectamine 2000 (according to the manufacturer’s protocol) or calcium 537 
phosphate method (44); using a total of 1.0 Pg of plasmid DNA. Cells were 538 
transfected with plasmids expressing NHERF-2, HPV-16 E6, HPV-16 E6 ΔPBM, 539 
HPV-18 E6, HPV-18 E6 ΔPBM alone or in combination as indicated in Figures and/or 540 
corresponding Figure legends. In order to monitor transfection efficiency, cells were 541 
co-transfected with E-galactosidase (LacZ) and checked by Western blot using the 542 
appropriate antibody. 16 h after transfection, media was aspirated, cells washed with 543 
sterile PBS, counted and seeded at 0.3 x 104 cells per well to a final volume of 100 Pl 544 
in a 96-well plate and incubated for a further 10 h for cells to attach. Cell proliferation 545 
was monitored using the Uptiblue reagent (Interchim) as previously described (51). 546 
Uptiblue reagent (5%, v/v) was added to the culture medium and fluorescence 547 
measured (ex 540 nm/em 590 nm) on a Tecan fluorescence multi-well plate reader 548 
(Tecan Group Ltd., Männedorf, Switzerland) after 48 h. Results are expressed as a 549 
percentage of cell number of untransfected cells or that of the EV ± SEM vs. 550 
transfected cells or untransfected cells.  551 
 552 
Wound healing/Scratch assay 553 
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A monolayer scratch/wound healing assay was employed as previously described 554 
(PMID:27483446). Briefly, C33-A, CaSki, HeLa, HFK and HFK containing the HPV 555 
16E6 genome (HFK_HPV16 E6) cells were each transfected with a control siRNA 556 
(siLuc) or NHERF-2 siRNA (siNHERF-2) as indicated. After 48 h, a scratch wound 557 
was generated in the confluent cells with a sterile Artline p2 pipette tip (Thermo 558 
Scientific). Wounds were immediately photographed under a microscope using the 559 
Dino-Eye Digital Eye Piece Camera [AM7023(R4), IDCP B.V. Naarden – The 560 
Netherlands] that was connected to a computer and the DinoCapture 2.0: Microscope 561 
Imaging Software. After a further 24 h, the wounds were photographed again and 562 
wound closure was calculated: images were saved as TIFF and gap areas measured 563 
using the MRI Wound Healing Tool macro for ImageJ software (NIH) 564 
(http://dev.mri.cnrs.fr/projects/ imagejmacros/wiki/Wound_Healing_Tool). The cells 565 
were then harvested in RIPA lysis buffer and NHERF-2 protein levels were analyzed 566 
by Western blot. Eactin was used as a loading control.  567 
 568 
Western blotting 569 
Extraction of cellular proteins was performed as previously described (31). In brief, 570 
following incubation of cells with the proteasome inhibitors, cells were collected in 571 
cold phosphate buffer saline (PBS), pH 7.4 and centrifuged together with the cell 572 
culture medium at 4°C and 250 x g for 4 min. After two washing steps with cold PBS, 573 
cells were lysed with 100 Pl of RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 574 
0.5% sodium desoxycholate, 1% Triton X-100, 0.1% sodium dodecyl sulfate (SDS)) 575 
supplemented with the protease inhibitors Cocktail Set I (Calbiochem) according to 576 
the manufacturer's instructions. The cell lysate was left on ice for 15 min, subjected 577 
to sonification (3 x 1 min) at 4°C and then cell debris was removed by centrifugation 578 
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at 16,250 x g at 4°C for 10 min. The protein content of the supernatant was 579 
determined according to the Bradford method using the Bio-Rad protein assay 580 
reagent (Bio-Rad). 581 
Proteins were separated on either a 10 or 12% sodium dodecyl sulfate-582 
polyacrylamide gel and transferred onto a nitrocellulose membrane by tank blotting. 583 
The membrane was blocked with 5% dry milk in PBS containing 0.1% Tween-20 for 1 584 
h at room temperature and then incubated with the specific antibody, which was 585 
diluted in PBS with 0.1% Tween-20 containing 1% dry milk powder. The membrane 586 
was washed with PBS Tween-20 containing 1% skimmed milk (3 x 10 min), before 587 
being incubated with a peroxidase-coupled secondary antibody (anti-rabbit 1:1000 or 588 
anti-mouse 1:1000) for 1 h at room temperature. The membrane was washed again 589 
in PBS Tween-20 (3 x 10 min). Signals were developed, visualized and quantified 590 
using the Uvitec Cambridge – Alliance 4.7 imaging system (Cleaver Scientific, 591 
Rugby, Warwickshire, UK). 592 
 593 
Statistical analysis 594 
GraphPad Prism (GraphPad Inc., USA) software was used to analyze the data. All 595 
values are averages of at least 3 independent experiments made in triplicates, except 596 
when specified. Error bars shown in the figures represent standard error of the mean 597 
(SEM) and all results were expressed as arithmetic mean ± SEM. Differences 598 
between the experimental groups were analyzed using one-way ANOVA or student’s 599 
t-test (two-tail, unpaired), statistical significant differences were shown as p ≤ 0.05. 600 
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 765 
FIGURE LEGENDS 766 
Fig. 1. HPV-16 E6, -18 E6 and -33 E6 proteins bind to NHERF-2 in vitro and in vivo.  767 
A)  Radiolabeled in vitro translated NHERF-2 was incubated with GST-16 E6, GST-768 
18 E6, GST-33 E6 and GST-18 E6∆PBM or GST alone for control. Bound proteins 769 
were assessed by autoradiography, and the input GST fusion proteins were 770 
visualized with Coomassie staining (lower panel). Input NHERF-2 (20%) is shown.  771 
B) The assay was repeated including GST-HPV-16 E6∆PBM and GST-HPV-33 772 
E6∆PBM.  C) HEK-293 cells were transfected with HA-tagged NHERF-2. After 24 h 773 
cells were harvested and cell lysates were incubated with the indicated GST fusion 774 
proteins. GST alone was included as a control.  After extensive washing, bound 775 
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NHERF-2 was detected by Western blotting using the anti-HA antibody and is 776 
compared with the amount of NHERF-2 present in 10% of the input.  The lower panel 777 
shows the positions of purified GST proteins used in the pull downs visualized with 778 
Coomasie staining.  D) C33-A cell extracts were incubated with indicated GST fusion 779 
proteins.  After extensive washing, bound NHERF-2 was detected by Western 780 
blotting using the anti-NHERF-2 antibody and is compared with the amount of 781 
NHERF-2 present in 10% of the input. The lower panel shows the positions of 782 
purified GST proteins used in the pull downs visualized with Coomasie staining. 783 
 784 
Fig. 2. A number of HR HPV E6 proteins direct proteasome-mediated degradation of 785 
NHERF-2 in vitro and in vivo. A) NHERF-2, 16 E6, 18 E6, 33 E6 and 11 E6 were 786 
translated, and co-incubated at 30 °C for the times indicated.  Residual NHERF-2 787 
was then detected by SDS-PAGE and autoradiography.  The E6 inputs are shown in 788 
the lower panel (lower band in each case - arrowed). Note the higher mobility of 789 
HPV-18 E6, in agreement with previously published data (36). B) Plasmid expressing 790 
NHERF-2 (HA- NHERF-2) was overexpressed in HEK-293 cells alone or in 791 
combination with HPV 16 E6, 18 E6, 11 E6 or 33 E6. Twenty-four hours after 792 
transfection, cells were incubated with or without the proteasome inhibitor (BTZ) for a 793 
further 10 h before harvesting.  Cell lysates were prepared and analyzed by Western 794 
blotting using anti HA-antibody. E-galactosidase (LacZ) was used as an internal 795 
standard to monitor transfection efficiency and loading control. Relative densitometry 796 
for HA-NHERF-2 under various transfection conditions is shown in B (lower panel). 797 
The mean values ± standard error of 3 independent experiments is shown. *p < 0.05; 798 
**p<0.01; ns, not statistically significant. C) NHERF-2 protein levels were analyzed by 799 
Western blotting in cell lysates from C33-A (HPV negative), HeLa (HPV-18 positive), 800 
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CaSki and SiHa (both HPV-16 positive). D) The same cell lines were treated with 801 
either DMSO or BTZ for 10 h. Cell lysates were then prepared and analyzed by 802 
Western blotting using anti-NHERF-2 antibody. In both C and D, p53 was used as a 803 
control for proteasome inhibition, while E-actin was used as a loading control.  804 
 805 
Fig. 3.  HPV E6 degradation of NHERF-2 is PBM dependent.  HA-tagged NHERF-2 806 
was overexpressed in HEK-293 cells alone or in combination with HPV-16 E6 or -18 807 
E6; or with their respective mutants 16 E6ΔPBM or 18 E6ΔPBM as indicated. As a 808 
negative control, HEK-293 cells were also transfected with the empty vector (EV).  809 
After 24 h of transfection, cells were harvested, lysates prepared and analyzed for 810 
NHERF-2 protein expression by Western blotting using anti-HA antibody. The 811 
expression of E-galactosidase (LacZ) was used as an internal standard to monitor 812 
transfection efficiency and loading (lower panel).  Relative densitometry for HA-813 
NHERF-2 under various transfection conditions is shown in the lower panel. The 814 
mean values ± standard error of 3 independent experiments is shown. *p < 0.05; 815 
**p<0.01; ns, not statistically significant. 816 
 817 
Fig. 4.  HPV-16 E6 and -18 E6 target nuclear pool of NHERF-2.  A) HeLa and CaSki 818 
cells were transfected with the indicated siRNAs.  After 72 h they were harvested and 819 
subjected to Western blot analysis using NHERF-2 antibody. p53 served as a control 820 
for E6/E7 and E6AP ablation. Overall protein loading was verified using anti-D-actinin 821 
antibody.  B) Hela, C) CaSki and D) SiHa cells were transfected with siRNA 822 
Luciferase (siLuc), siRNA E6/E7 (siE6/E7) and siRNA E6AP (siE6AP). After 72 h the 823 
cells were fixed and stained for NHERF-2 and for p53, which served as a control for 824 
the E6/E7 and E6AP knockdown. E) HPV-16 E6 was overexpressed in HFK cells and 825 
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non-transfected cells were used a negative control.  After 72 h the cells were fixed 826 
and stained for NHERF-2 and for p53, which served as a control for E6 transfection. 827 
Scale bar; B,D and D - 20 µm; E - 10 µm. 828 
 829 
Fig. 5. HPV regulates p27 protein expression by targeting NHERF-2. A) HA-tagged 830 
NHERF-2 was overexpressed in HEK-293 cells alone or in combination with HPV 16 831 
E6 or 18 E6; or with their respective mutants HPV- 16 E6ΔPBM or HPV-18 E6ΔPBM 832 
as indicated. As a negative control, HEK-293 cells were transfected with the EV. E-833 
galactosidase (LacZ) was used as an internal standard to monitor transfection 834 
efficiency and Jtubulin was used for loading control. After 24 h of transfection, cells 835 
were harvested and lysates prepared and analyzed by Western blotting for the 836 
protein expressions of p27 and NHERF-2 using anti-p27 and anti-NHERF-2 837 
antibodies. Relative densitometries for p27 and NHERF-2 under various transfection 838 
conditions are shown in A (lower panel).  B) Cell lysates from A were used to check 839 
for the protein expression levels of HA-NHERF-2, CyclinD1 and CDK4. Relative 840 
densitometries for CyclinD1 and CDK4 under various transfection conditions are 841 
shown in B (lower panel).  E-galactosidase (LacZ) was used as an internal standard 842 
to monitor transfection efficiency and Jtubulin was used for loading control. C) HEK-843 
293 cells were co-transfected with the indicated plasmids alone or the EV or in 844 
combination with the control siRNA luciferase (siLuc) or NHERF-2 siRNA (siNHERF-845 
2).  Twenty-four hours after transfection, cells were harvested and whole cell lysates 846 
prepared and analyzed by Western blot using the various antibodies as indicated.  E- 847 
galactosidase (LacZ) was used as an internal standard to monitor transfection 848 
efficiency, while E-actin was used as a loading control. Relative densitometries for 849 
p27 and HA-NHERF-2 under various transfection conditions are shown in C (lower 850 
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panel). One representative of at least 3 independent Western blots is shown. Data 851 
are expressed as a fold change relative to J-tubulin (A and B) or to E-actin (C). In 852 
each case, the mean values ± standard error of 3 independent experiments is shown.  853 
*p < 0.05; **p<0.01; ns, not statistically significant. D-E) HeLa and CaSki cells were 854 
transfected with siRNA directed against luciferase (siLuc), E6/E7 (siE6/E7), E6AP 855 
(siE6AP) and NHERF-2 (siNHERF-2), alone or in combination.  After 72 h cells were 856 
harvested and the levels of NHERF-2, p53, p27, and the D-actinin loading control 857 
were detected by Western blotting.  F) NHERF-2, p53 and p27 protein levels were 858 
analyzed by Western blotting in cell lysates from C33-A (HPV negative), HeLa (HPV-859 
18 positive), CaSki and SiHa  860 
(both HPV-16 positive).E-actin was used as a loading control and in each case, on  861 
representative of at least three independent Western blots is shown. 862 
 863 
Fig. 6. HPV E6 increases cellular proliferative capacity by degrading NHERF-2. A) 864 
HEK-293 cells were transfected with the EV or with plasmids expressing HA-tagged 865 
NHERF-2, 16 E6 and 16 E6ΔPBM, alone or in combination as indicated. B) HEK-293 866 
cells were transfected with the EV or with plasmids expressing HA-tagged NHERF-2, 867 
18 E6 and 18 E6ΔPBM alone or in combination as indicated. After 48 h of 868 
transfection, cell proliferation was analyzed as described in the “Materials and 869 
Methods” section. In all the experiments, data are expressed as a percentage 870 
change relative to EV transfected cells, which was normalized to 100%. In each case, 871 
the mean values ± standard error of 3 independent experiments is shown.  *p < 0.05; 872 
**p<0.01; ns, not statistically significant.  C) Confluent cells (C33-A, CaSki, HeLa, 873 
HFK and HFK containing HPV 16E6 genome (HFK_HPV16 E6) cells) were scratched 874 
with a plastic pipette tip 48 h after being transfected with either siLuc or siNHERF-2. 875 
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C) Cells were photographed to capture gaps immediately post-scratch (0 h) and after 876 
24 h. The bar chart shows percentage area of gap closure at 24 h. The same cells 877 
were then harvested, lysed and NHERF-2 protein levels analyzed by Western blot. 878 
E-actin was used as a loading control. Data are presented as means ±SD from three 879 
independent experiments. *p < 0.05; **p<0.01 to control (siLuc). 880 
 881 
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